Home/Filings/4/0001615774-18-001116
4//SEC Filing

RAUSCH CARL W 4

Accession 0001615774-18-001116

CIK 0001473579other

Filed

Feb 12, 7:00 PM ET

Accepted

Feb 13, 4:30 PM ET

Size

16.4 KB

Accession

0001615774-18-001116

Insider Transaction Report

Form 4
Period: 2017-08-14
RAUSCH CARL W
DirectorCEO
Transactions
  • Purchase

    Series A Preferred Stock

    2017-08-14$0.10/sh+1,000,000$100,0001,000,000 total
    Exercise: $0.10From: 2017-08-14Common Stock (1,000,000 underlying)
  • Purchase

    Common Stock Purchase Warrants

    2017-08-14$0.15/sh+2,000,000$300,0002,000,000 total
    Exercise: $0.15From: 2017-08-14Exp: 2022-08-14Common Stock (2,000,000 underlying)
  • Purchase

    Common Stock Purchase Warrants

    2018-02-02$0.15/sh+2,000,000$300,0002,000,000 total
    Exercise: $0.15From: 2018-02-02Exp: 2023-02-02Common Stock (2,000,000 underlying)
  • Purchase

    Series A Preferred Stock

    2018-02-02$0.10/sh+1,000,000$100,0001,000,000 total
    Exercise: $0.10From: 2018-02-02Common Stock (1,000,000 underlying)
Holdings
  • Stock Options

    Exercise: $0.20From: 2016-08-12Exp: 2021-08-12Common Stock (6,000,000 underlying)
    6,000,000
  • Stock Options

    Exercise: $0.18From: 2015-03-25Exp: 2026-08-12Common Stock (500,000 underlying)
    500,000
  • Stock Options

    Exercise: $0.10From: 2011-09-15Exp: 2026-08-12Common Stock (1,500,000 underlying)
    1,500,000
Footnotes (2)
  • [F1]The options vest in three equal tranches of 2,000,000 upon the Company the Company raising $1,000,000 in financing, the Company raising $5,000,000 in financing and the Company entering into a significant corporate alliance for substantial marketing and selling of the Company's product portfolio. The initial tranche is exercisable at $0.20 per share, the second tranche will be $0.40 per share and the third tranche will be $0.60 per share, which such vesting is subject to continued employment as an executive with the Company as of the vesting date. The expiration date is five years from the date of grant.
  • [F2]On August 14, 2017 and February 2, 2018, World Technology East II Limited ("WTE") acquired 10,000 shares of Series A Preferred Stock and common stock purchase warrants to acquire 2,000,000 shares of common stock on each date. Mr. Rausch and Conroy Cheng each equally control WTE and share dispositive and voting control over such securities.

Issuer

Boston Therapeutics, Inc.

CIK 0001473579

Entity typeother

Related Parties

1
  • filerCIK 0001233999

Filing Metadata

Form type
4
Filed
Feb 12, 7:00 PM ET
Accepted
Feb 13, 4:30 PM ET
Size
16.4 KB